CLINICAL_TRIALS
trial_result
· 2020-03-17
Clinical Trial Update: Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Summary
Phase 3 study of ixekizumab in children aged 6 to under 18 with moderate-to-severe plaque psoriasis completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2020-03-17